Australian TGA Approves Key Label Updates To Camurus’ Buvidal To Treat Opioid Dependence

Camurus announced that the Australian regulatory agency, the Therapeutic Goods Administration (TGA), has approved key label updates to Buvidal Weekly and Buvidal Monthly (buprenorphine) modified-release solutions for injection.The approval includes: a new higher Buvidal Monthly 160 mg dose, direct initiation onto Buvidal Weekly, removing the requirement to be stabilised on sublingual buprenorphine prior to commencing treatment with Buvidal and changing the contraindications in pregnancy and lactation to precautions.In 2020 over 53,000 Australians received treatment for their opioid dependence, which represents a 4.7% increase on the previous year. This was the largest increase in treatment delivery in the past decade and has been attributed to the introduction of long-acting injectable buprenorphine treatment which has increased treatment access and capacity.“This welcome approval by the TGA provides additional opportunities to individualize treatment with Buvidal according to patients medical needs”, says Fredrik Tiberg, PhD, president & CEO. “Aligned with the EU label, Australian patients can now be directly initiated directly onto Buvidal Weekly, allowing a rapid transfer to long-acting therapy and avoiding the need for daily dosing.”Camurus will now initiate the process for reimbursement for the 160 mg dose through the Pharmaceutical Benefits Advisory Committee process.Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!